VEGF administration inhibits DA neurons loss in PD models, especially in the substantia nigra and in the striatum (Sheikh et al., 2017), thus representing a potential therapeutic target for prevention of DA neuron death and PD progression. This evidence concerns the gene VEGFA and Parkinson disease.